quinoxalines has been researched along with tx 402 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hori, H; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ohnishi, K; Ohnishi, T; Ono, K; Suzuki, M; Takahashi, A; Uto, Y | 1 |
| Hori, H; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Suzuki, M; Uto, Y | 1 |
| Hori, H; Kinashi, Y; Maruhashi, A; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Sakurai, Y; Suzuki, M; Uto, Y | 1 |
| Hori, H; Ide, T; Kitajima, Y; Miyazaki, K; Miyoshi, A; Nagasawa, H; Ohtaka, K; Uto, Y | 1 |
| Morishige, K; Nagasawa, H; Nozawa-Suzuki, N; Ohnishi, K | 1 |
5 other study(ies) available for quinoxalines and tx 402
| Article | Year |
|---|---|
Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Cyclic N-Oxides; Gamma Rays; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Micronucleus Tests; Mutation; Organophosphorus Compounds; Quinoxalines; Radiotherapy; Tirapazamine; Triazines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2005 |
The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclic N-Oxides; Female; Fluorescent Antibody Technique; Hyperthermia, Induced; Mice; Mice, Inbred C3H; Micronucleus Tests; Neoplasm Transplantation; Neoplasms; Quinoxalines; Tirapazamine; Triazines | 2005 |
The usefulness of mild temperature hyperthermia combined with a newly developed hypoxia-oriented 10B conjugate compound, TX-2100, for boron neutron capture therapy.
Topics: Animals; Borohydrides; Boron Compounds; Boron Neutron Capture Therapy; Carcinoma, Squamous Cell; Cell Proliferation; Cell Survival; Combined Modality Therapy; Cyclic N-Oxides; Female; Fluorescent Antibody Technique; Hyperthermia, Induced; Hypoxia; Mice; Mice, Inbred C3H; Micronucleus Tests; Quinoxalines; Quinuclidines; Sulfhydryl Compounds; Time Factors; Tissue Distribution; Tumor Cells, Cultured | 2006 |
Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner.
Topics: Carcinoma, Hepatocellular; Cell Growth Processes; Cell Hypoxia; Cell Movement; Cyclic N-Oxides; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Matrix Metalloproteinases; Neoplasm Invasiveness; Proto-Oncogene Protein c-ets-1; Quinoxalines; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Up-Regulation | 2006 |
The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cyclic N-Oxides; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplastic Stem Cells; Octamer Transcription Factor-3; Ovarian Neoplasms; Ovary; Quinoxalines | 2015 |